QR Code

Doxorubicin-Loaded Polymeric Micelles Conjugated with CKR- and EVQ-FLT3 Peptides for Cytotoxicity in Leukemic Stem Cells

Doxorubicin (Dox) is the standard chemotherapeutic agent for acute myeloblastic leukemia (AML) treatment. However, 40% of Dox-treated AML cases relapsed due to the presence of leukemic stem cells (LSCs). Thus, poloxamer 407 and CKR- and EVQ-FLT3 peptides were used to formulate Dox-micelles (DMs) and...

Whakaahuatanga katoa

I tiakina i:
Ngā kaituhi matua: Fah Chueahongthong, Singkome Tima, Sawitree Chiampanichayakul, Pornngarm Dejkriengkraikul, Siriporn Okonogi, Mathurada Sasarom, Soraya Rodwattanagul, Cory Berkland, Songyot Anuchapreeda
Hōputu: Artigo
Reo:Inglês
I whakaputaina: MDPI AG 2022-10-01
Rangatū:Pharmaceutics
Ngā marau:
doxorubicin
CKR
EVQ
polymeric micelle
leukemic stem cell
co-treatment
Urunga tuihono:https://www.mdpi.com/1999-4923/14/10/2115
Ngā Tūtohu: Tāpirihia he Tūtohu
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!

Ngā tūemi rite